Psychedelic for resistant depression

Recently, studies on the therapeutic properties of psychedelics have become quite popular. Therefore, the Irish company GH Research did not miss the opportunity and raised new funds to develop its own candidate.

A biotech company is rapidly developing its leading candidate – the inhaler GH001 for the treatment of neurological and psychological disorders. The company begins its clinical program with the most lucrative indication – resistant depression. To date, GH001 has completed a phase 1 study that was conducted in volunteers exclusively. The results have shown that the drug is well-tolerated and is currently undergoing a phase 1/2 trial in patients with persistent depression. GH001 has an official name - 5-Methoxydimethyltryptamine (5-MeO-DMT), also called "toad venom", as it occurs naturally in certain amphibians that live in the southwestern United States. It can still be obtained from plants or synthetically. The popularity of psychedelics has grown significantly in the mid-2010s, especially among people trying to achieve the phenomenon of "ego death".

Source: ENDPOINTS NEWS